Overview

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

Status:
Not yet recruiting

Trial end date:
2024-01-31

Target enrollment:

Participant gender:

Summary

The hypothesis is that the addition of mycophenolate mofetil (MMF) and allopurinol to chemotherapy in patients with relapsed small cell lung cancer (SCLC) will be safely tolerated and improve outcomes, as measured by response rate and progression-free survival in patients compared to other single agent chemotherapy drugs used in historical controls.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Allopurinol
Irinotecan
Mycophenolic Acid